JAZZ vs BNTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
JAZZ · Jazz Pharmaceuticals$230.26 ▼ 2.62%
BNTX · BioNTech$80.96 ▼ 0.52%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- JAZZ +27.3%
- BNTX -16.1%
Head to head
| Metric | JAZZ | BNTX |
|---|---|---|
| Price | $230.26 | $80.96 |
| Change today | ▼ 2.62% | ▼ 0.52% |
| Market cap | $14.78B | $20.07B |
| Return, 3 months | -9.5% | -28.2% |
| Return, year to date | +35.4% | -15.0% |
| Return, 1 year | +30.1% | -15.3% |
| P/E (TTM) | 68.1 | – |
| P/B | 3.5 | 1.0 |
| P/E percentile vs own 5y | 88th | 44th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +10.4% | -15.1% |
| Net profit growth (YoY) | -292.3% | +742.9% |
| Gross margin | 89.1% | 75.0% |
| Operating margin | 24.0% | -72.7% |
| Net margin | 4.4% | -60.9% |
| Return on equity | 5.1% | -8.1% |
| Analyst target vs. price | +33.4% | +47.4% |
| Analyst buy share | 100% | 75% |
| RSI (14) | 49 | 31 |
| 30-day volatility | 41.4% | 35.9% |
| Max drawdown, 1 year | -21.6% | -32.2% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- BNTX is the largest of the group by market value.
- JAZZ has returned the most over the past year.
- JAZZ is growing revenue fastest.
- JAZZ keeps the most profit per dollar of sales.
- BNTX has been the calmest stock over the last 30 days.